Genetic Technologies (STU:DU8) Total Liabilities : €2.24 Mil (As of Dec. 2023)

View and export this data going back to . Start your Free Trial

What is Genetic Technologies Total Liabilities?

Genetic Technologies's Total Liabilities for the quarter that ended in Dec. 2023 was €2.24 Mil.

Genetic Technologies's quarterly Total Liabilities declined from Jun. 2023 (€2.29 Mil) to Sep. 2023 (€0.00 Mil) but then increased from Sep. 2023 (€0.00 Mil) to Dec. 2023 (€2.24 Mil).

Genetic Technologies's annual Total Liabilities increased from Jun. 2021 (€0.91 Mil) to Jun. 2022 (€2.91 Mil) but then declined from Jun. 2022 (€2.91 Mil) to Jun. 2023 (€2.29 Mil).

Genetic Technologies Total Liabilities Historical Data

The historical data trend for Genetic Technologies's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genetic Technologies Total Liabilities Chart

Genetic Technologies Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Total Liabilities

Get a 7-Day Free Trial

0.92

1.01

0.91

2.91

2.29

Genetic Technologies Quarterly Data
	Jun18	Dec18	Jun19	Dec19	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Liabilities	Get a 7-Day Free Trial															-	2.29	-	2.24	-

Genetic Technologies Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Genetic Technologies's Total Liabilities for the fiscal year that ended in Jun. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	2.052	+	(0.142	+	0.018
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0.076	+	0)
	=	2.29

Total Liabilities	=	Total Assets (A: Jun. 2023 )	-	Total Equity (A: Jun. 2023 )
	=	9.203	-	6.915
	=	2.29

Genetic Technologies's Total Liabilities for the quarter that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	2.1	+	(0.052	+	0.029
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0.062	+	0)
	=	2.24

Total Liabilities	=	Total Assets (Q: Dec. 2023 )	-	Total Equity (Q: Dec. 2023 )
	=	5.197	-	2.954
	=	2.24

Genetic Technologies Total Liabilities Related Terms

Thank you for viewing the detailed overview of Genetic Technologies's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Genetic Technologies (STU:DU8) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Genetic Technologies Ltd (STU:DU8) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

GENE:USA GTG:Australia

Address

60-66 Hanover Street, Fitzroy, Melbourne, VIC, AUS, 3065

Website

https://www.gtglabs.com

Genetic Technologies Ltd is an Australia-based molecular diagnostics company that offers predictive testing and assessment tools to help physicians proactively manage women's health. The company has developed BREVAGenplus which is a clinically validated risk assessment test for non-hereditary breast cancer. It also provides genetic testing services including medical testing, animal testing, forensic testing, and plant testing. The company markets BREVAGenplus to healthcare professionals in breast healthcare and imaging centers, as well as to obstetricians/ gynecologists (OBGYNs) and breast cancer risk assessment specialists. The majority of the company's revenue is generated from Australia and the United States. The group has two operating segments: EasyDNA and GeneType/Corporate.

Genetic Technologies (STU:DU8) Headlines

No Headlines